Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
In the present study, we investigated possible alterations in red blood cell (RBC) deformability, plasma and whole blood viscosities (WBV) and hematological parameters in response to Yo-Yo intermittent recovery test level 1 (Yo-YoIR1) which is currently used to assess endurance performance, in female volleyball players. Eight volleyball player volunteers from Pamukkale University (mean age19,9 ± 2,2 years; mean body height 177.5 ± 1.99 cm; mean body mass index 21.66 ± 0.64 kg/m2) participated to the study. Blood samples were collected before and immediately after test. Red blood cell (RBC) deformability was determined by ektacytometer, plasma and whole blood viscosities (WBV) by a cone-plate rotational viscometer. Hematological parameters were determined using an electronic hematology analyzer. The Yo-YoIR1 applied, induced acute increments in WBV at native hematocrit (Hct) measured at a shear rate of 150 s-1 and 375 s-1, RBC deformability and WBC count. The results of the current study indicate that, the Yo-Yo IR1 test used to determine physical capacity of the player, by resulting in increments in RBC deformability contributes blood flow and thus, athletic performance of the individual.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3233/CH-141844 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alterations in erythrocyte deformability, aggregation, and blood viscosity in rheumatoid arthritis and systemic lupus erythematosus patients: A comparative haemorheological analysis.
Clin Hemorheol Microcirc
September 2025
Department of Internal Medicine, Sultan Abdülhamid Han Research & Training Hospital, University of Health Sciences, Istanbul, Turkey.
ObjectivesThis study investigated haemorheological alterations in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).MethodsA total of 136 individuals were enrolled, comprising 52 healthy controls, 51 RA patients, and 33 SLE patients. Blood samples were collected at the University of Health Sciences Sultan Abdulhamid Han Training and Research Hospital in Istanbul, Türkiye.
View Article and Find Full Text PDFRed blood cell extracellular vesicles: new frontiers in hematological biomarker discovery.
Front Med (Lausanne)
August 2025
Department of Zoology, Biomedical Technology, Human Genetics & Wildlife Biology and Conservation, School of Sciences, Gujarat University, Ahmedabad, India.
Extracellular vesicles (EVs) offer promising opportunities in hematology for improved diagnostics, prognostics, and therapeutics, making them valuable tools in the molecular landscape. EVs derived from red blood cells (RBCs) are the primary source of EVs in the bloodstream. They perform several critical biological and physiological functions, such as facilitating intercellular communication and transferring biomolecules like DNA, RNA, and proteins.
View Article and Find Full Text PDFStudy on the relationship between homocysteine and general metabolic indexes in healthy population in Hebei Province, China.
Front Endocrinol (Lausanne)
September 2025
Department of Physical Examination Center, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Background: The aging problem is a significant issue and challenge currently faced by the whole world. Hyperhomocysteinemia (HHcy) is a common phenomenon among the older adult. Increasing evidence suggests a link between HHcy and multiple systemic issues in the older adult-related diseases.
View Article and Find Full Text PDFSafety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First-in-Human Studies in Healthy Participants and Patients.
Clin Pharmacol Ther
September 2025
Pfizer Inc, New York, New York, USA.
The investigational agent osivelotor, a small molecule hemoglobin (Hb) modifier in development for the treatment of sickle cell disease (SCD), acts by increasing Hb-oxygen affinity and inhibiting the polymerization of sickle Hb. We report safety, pharmacokinetic (PK), and pharmacodynamic (PD) data from the first two phase 1 clinical trials of osivelotor in healthy participants and participants with SCD. Healthy participants (N = 129) were randomized to receive either osivelotor or placebo in single-ascending doses (50-3,000 mg) or multiple-ascending doses (loading doses, then 15-100 mg once-daily maintenance doses through 14 days).
View Article and Find Full Text PDFA Microfluidic Approach for Assessing the Rheological Properties of Healthy Versus Thalassemic Red Blood Cells.
Micromachines (Basel)
August 2025
Shenzhen Bay Laboratory, Institute of Biomedical Engineering, Shenzhen 518107, China.
The deformability of red blood cells (RBCs) is critical for microvascular circulation and is impaired in hematological disorders such as thalassemia, a prevalent public health concern in Guangdong, China. While microfluidics enable high-precision deformability assessment, current studies lack standardization in deformation metrics and rarely investigate post-deformation recovery dynamics. This study introduces an automated microfluidic platform for systematically evaluating RBC deformability in healthy and thalassemic individuals.
View Article and Find Full Text PDF